Recombinant adenovirus vectors for gene therapy and clinical trials (a review)

Acta Microbiologica et Immunologica Hungarica

Volumn 48, Issue 3-4, 2001, Pages 323-348

  Nász, István ^a   Ádám, Éva ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Adenovirus; Adenovirus genome; Clinical trials; Recombinant adenovirus vectors

Indexed keywords

ADENOVIRUS; CHIMERA; CLINICAL TRIAL; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETIC RECOMBINATION; GENETICS; HELPER VIRUS; HUMAN; IMMUNOLOGY; NEOPLASM; REVIEW; VIRUS CAPSID;

ADENOVIRIDAE; CAPSID; CHIMERA; CLINICAL TRIALS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HELPER VIRUSES; HUMANS; NEOPLASMS; RECOMBINATION, GENETIC;

EID: 0035756435     PISSN: 12178950     EISSN: None     Source Type: Journal    
DOI: 10.1556/AMicr.48.2001.3-4.6     Document Type: Review

References (108)

1. Russel, W.C., Adrian, T., Bartha, A., Fujinaga, K., Ginsberg, H.S., Hierholzer, J.C., de Jong, J.C., Li, Q.G., Mautner, V., Nász, I., Wadell, G.: Adenoviridae. In: Virus taxonomy. Sixth report of the International Committee on Taxonomy of Viruses. Eds.: Murphy, F.A., Fauquet, C.M., Bishop, D.H.L.: Arch Virol Suppl 10, 128 (1996)
2. Hitt, M.M., Graham, F.L.: Adenovirus vectors for human gene therapy. Adv Virus Res 55, 479 (2000)
3. Kulcsár, G., Csata, S., Nász, I.: Isolation of an infectious oncogenic adenovirus strain from the stimulated lymphocytes of a patient with bladder tumor. Acta Microbiol Hung 38, 91 (1991)
4. Csata, S., Kulcsár, G., Dán, P., Horváth, J., Nász, I.: Adenovirus antibodies in tumorous diseases of the urogenital system. Acta Chirurg Acad Sci Hung 23, 15 (1982)
5. Randrianarison-Jewtoukoff, V., Perricaudet, M: Recombinant adeno-viruses as vaccines. Biologicals 23, 145 (1995)
6. Leppard, K.N.: E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infection. J Gen Virol 78, 2131 (1997)
7. Berkner, K.L.: Development of adenovirus vectors for the expression of heterologous genes. Bio Techniques 6, 616 (1986)
8. Lee, M.G., Abina, M.A., Perricaudet, M.: The constitutive expression of the immunomodulatory gp 19k protein in E1-, E3-adenoviral vectors strongly reduces the host T cell response against the vector. Gene Ther 2, 256 (1995)
9. Graham, F.L., Smiley, J., Russel, W.C., Nairn, R.: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Virology 186, 59 (1977)
10. Davis, A.R., Meyers, K., Wilson, J.M.: High throughput method for creating and screening recombinant adenoviruses. Gene Ther 5, 1148 (1998)
11. Hitt, M.M., Addison, C.L., Graham, F.L.: Human adenovirus vectors for gene transfer into mammalian cells. In: Advances in Pharmacology, Ed.: August, T. 40, 137 (1997)
12. Gabaglia, C.R., Pedersen, B., Hitt, M., Burdin, N., Sercarz, E.E., Graham, F.L., Gauldie, J., Braciak, T.A.: A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10D2 mice. J Immunol 162, 753 (1999)
13. Old, J.L.: Immunotherapy for cancer. Sci Am 275, 102 (1996)
14. Stewart, A.K., Lassam, N.J., Quirt, I.C., Bailey, D.J., Rotstein, L.E., Krajden, M., Dessureault, S., Gallinger, S., Cappe, D., Wan, Y., Addison, C.L., Moen, R.C., Gauldie, J., Graham, F.L.: Adenoviral-mediated gene delivery of interleukin-2 in metastatic breath cancer and melanoma: results of a phase I clinical trial. Gene Ther 6, 350 (1999)
15. Wilson, J.M.: Gene therapy for cystic fibrosis: challenges and future directions. J Clin Invest 96, 2547 (1995)
16. Habib, N.A., Hodgson, H.J., Lemoine, N., Pignatelli, M.: A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad metastatic malignant liver tumours. Hum Gene Ther 10, 2019 (1999)
17. Zwacka, R.M., Dunlop, M.G.: Gene therapy for colon cancer. Hematol Oncol Clin North Am 12, 595 (1998)
18. Eastham, J.A., Hall, S.J., Seghal, I., Wang, J., Timme, T.L., Yang, G., Connell-Crowley, L., Elledge, S.J., Zhang, W.W., Harper, J.W.: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55, 5151 (1995)
19. Alvarez, R.D., Gomez-Navarro, J., Wand, M., Barnes, M.N., Strong, T.V., Arani, R.B., Arafat, W., Hughes, J.V., Siegal, G.P., Curiel, D.T.: Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2, 524 (2000)
20. Hasenburg, A., Tong, X.W., Rojas-Martinez, A., Nyberg-Hoffman, C., Kieback, C.C., Kaplan, A., Kaufman, R.H., Ramzy, I., Augilar-Cordova, E., Kieback, D.G.: Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 7, 839 (2000)
21. Sandmair, A.M., Loimas, S., Puranen, P., Immonen, A., Kossila, M., Puranen, M., Hurskainen, H., Tyynela, K., Turunen, M., Vanninen, R., Lehtolainen, P., Paljarvi, L., Johanson, R., Vapalahti, M., Yla-Herttuala, S.: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11, 2197 (2000)
22. Trask, T.W., Trask, R.P., Augilar-Cordova, E., Shine, H.D., Wyde, P.R., Goodman, J.C., Hamilton, W.J., Rojas-Martinez, A., Chen, S.H., Woo, S.L., Grossman, R.G.: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 1, 195 (2000)
23. Kong, H.L., Hecht, D., Song, W., Kovesdi, I., Hackett, N.R., Yayon, A., Crystal, R.G.: Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9, 823 (1998)
24. Lin, P., Buxton, J.A., Acheson, A., Radziejewski, C., Maisonpierra, P.C., Yancopoulos, G.D., Channon, K.M., Hale, L.P., Dewhirst, M.W., George, S.E., Peters, K.G.: Antiangiogenic gene therapy targeting the endothelium-specific tyrosine kinase Tie2. Proc Natl Acad Sci USA 95, 8829 (1998)
25. Wivel, N.A., Gao, G-P., Wilson, J.M.: Adenovirus vectors. In: The development of human gene therapy Ed: Friedman, T. 87, Cold Spring Harbor Lab Press, San Diego, CA (1999)
26. Kafri, T., Morgan, D., Krahl, T., Sarvetnick, N., Sherman, L., Verma, I.: Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression. Pro Natl Acad Sci USA 95, 11377 (1998)
27. Smith, T.A., White, B.D., Gardner, J.M., Kaleko, M., McClelland, A.: Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 3, 496 (1996)
28. Yang, Y., Trinchieri, G., Wilson, J.M.. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1, 890 (1995)
29. Mastrangeli, A., Harvey, B.G., Yao, J., Wolff, G., Kovesdi, I., Crystal, R.G., Falck-Pedersen, E.: "Sero-switch" adenovirus mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defense against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 7, 79 (1996)
30. Mack, C.A., Song, W.R., Carpenter, H., Wickham, T.J., Kovesdi, I., Harvey, B.G., Magovern, C.J., Isom, O.W., Rosengart, T., Falck-Pedersen, E., Hackett, N.R., Crystal, R.G., Mastrangeli, A.: Circumvention of anti-adenovirus neutralising immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 8, 99 (1997)
31. Ádám, É., Nász, I., Lengyel, A.: Characterization of adenovirus hexons by their epitope composition. Arch Virol 141, 1891 (1996)
32. Ádám, É., Nàsz, I., Hudecz, F., Lengyel, A., Mezo, G., Dobay, O.: Characterization of intertype specific epitopes on adenovirus hexons. Arch Virol 43, 1669 (1998)
33. Nász, I., Ádám, É., Lengyel, A.: Alternate adenovirus type-pairs for a possible circumvention of host immune response to recombinant adenovirus vectors. Acta Microbiol Immunol Hung 48, 141 (2001)
34. Imler, J.L., Chartier, C., Dreyer, D., Dieterlé, A., Saintemarie, M., Faure, T., Pavirani, A., Mehtali, M.: Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Ther 3, 75 (1996)
35. Krougliak, V., Graham, F.L.: Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 6, 1575 (1995)
36. Yeh, P., Perricaudet, M.: Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 11, 615 (1997)
37. Engelhardt, J.F., Ye, X., Doranz, B., Wilson, J.M.: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91, 6196 (1994)
38. Gao, G.P., Yang, Y., Wilson, J.M: Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 70, 8934 (1996)
39. Chirmule, N., Hughes, J.V., Gao, G.P., Raper, S.E., Wilson, J.M.: Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 72, 6138 (1998)
40. Brough, D.E., Hsu, C., Kulesa, V.A., Lee, G.M., Cantolupo, L.J., Lizonova, A., Kovesdi, I.: Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol 71, 9206 (1997)
41. Kochanek, S., Clemens, P., Mitani, K., Chen, H-H., Chan, S., Caskey, C.T.: A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA 93, 5731 (1996)
42. Lieber, A., He, C.Y., Kay, M.A.: Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat Biotechnol 15, 1383 (1997)
43. Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., Phipps, M.L.: Construction of adenovirus vectors through Cre.lox recombination. J Virol 71, 1842 (1997)
44. Hitt, M.M., Parks, R.J., Graham, F.L.: Structure and genetic organization of adenovirus vectors. In: The development of human gene therapy Ed: Friedman, T. 61, Cold Spring Harbor Lab Press, Cold Spring Harbor, N.Y. (1999)
45. Morral, N., O'Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P.A., Zhou, H., Parks, R., Velji, R., Aguilar-Cordova, E., Wadsworth, S., Graham, F., Kochanek, S., Carey, K.D., Beaudet, A.L.: Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 96, 12816 (1999)
46. Parks, R.J., Evelegh, C., Graham, F.L.: Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6, 1565 (1999)
47. Bilbao, G., Feng, M., Rancourt, C., Jackson, W.H., Curiel, D.T.: Adenoviral/retroviral vector chimeras: A novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J 11, 624 (1997)
48. Recchia, A., Parks, R.J., Lamartina, S., Toniatti, C., Pieroni, L., Palombo, F., Ciliberto, G., Graham, F.L., Cortese, R., La Monica, N., Colloca, S.: Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA 96, 2615 (1999)
49. Fisher, K.J., Kelley, W.M., Burda, J.F., Wilson, J.M.: A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 7, 2079 (1996)
50. Samulski, R.J., Zhu, X., Xias, X.: Targeted integration of adeno-associated virus (AAV) into human chromosome 19. Published erratum appears in EMBO J 11, 1228 (1992). EMBO J 10, 3941 (1991)
51. Krasnykh, V.N., Mikheeva, G.V., Douglas, J.T.: Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 70, 6839 (1996)
52. Rodrigues, E.G., Zavala, F., Nussenzweig, R.S., Wilson, J.M., Tsuji, M.: Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16, 1812 (1998)
53. Michael, S., Hong, J., Curiel, D., Engler, J.A.: Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 2, 660 (1995)
54. Douglas, J.T., Curiel, D.T.: Adenoviruses as vectors for gene therapy. Science and Medicine 4, 44 (1997)
55. Douglas, J.T., Rogers, B.E., Rosenfeld, M.E.: Targeted gene delivery by tropism-modified adenoviral vector. Nat Biotechn 14, 1574 (1996)
56. Rancourt, C., Rogers, B.E., Sosnowski, B.A., Wang, M., Piche, A., Frincke, J., Curiel, D.T.: Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 4, 2455 (1998)
57. Krasnykh, V., Dmitriev, I., Mikheeva, G., Miller, C.R., Belousova, N., Curiel, D.T.: Characterization of an adenovirus vector containing a heterologous peptide in the HI loop of the fiber knob. J Virol 72, 1844, (1998)
58. Wickham, T.J., Carrion, M.E., Kovesdi, I.: Targeting of adenovirus penton base to new receptors through replacement of its GRD motif with other receptor-specific motifs. Gene Ther 2, 750 (1995)
59. Wickham, T.J., Segal, D.M., Roelvink, P.W.: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70, 6831 (1996)
60. Wickham, T.J., Haskard, D., Segal, D., Kovesdi, I.: Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol Immunother 45, 149 (1997)
61. Nász, I., Ádám, É.,: New developments and trends in the adenovirus research (in Hungarian with English summary). Orv Hetil 138, 27 (1997)
62. Tournier-Lasserve, E.: Gene therapy and beyond. Lancet 354, 22 (2000)
63. Romano, G., Michell, P., Pacilio, C., Giordano, A.: Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18, 19 (2000)
64. Rosenfeld, M.A., Yoshimura, K., Trapnell, B.C., Yoneyama, K., Rosenthal, E.R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L.E., Stratford-Perricaudet, L.: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium Cell 68, 143 (1992)
65. Crystal, R.G., Jaffe, A., Brody, S., Mastrangeli, A., McElvaney, N.G., Rosenfeld, M., Chu, C-S., Danel, C., Hay, J., Eissa, T.: A phase I study in cytic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. Hum Gene Ther 6, 643 (1995)
66. Wilson, J., Engelhardt, J., Grossman, M., Simon, R., Yang, Y.: Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: phase 1 trial. Hum Gene Ther 5, 501 (1994)
67. Boucher, R., Knowles, M., Johnson, L., Olsen, J., Pickles, R., Wilson, J., Engelhardt, J., Yang, Y., Grossman, M.: Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase 1 trial in the nasal cavity. Hum Gene Ther 5, 615 (1994)
68. Wilott, R.W., Whitsett, J., Trapnell, B.: A phase I study of gene therapy of cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane conductance regulator cDNA to the airways. In: Federal Register 58, 21737 (1995)
69. Perricone, M.A., Rees, D.D., Sacks, C.R., Smith, K.A., Kaplan, J.M., St George, J.A.: Inhibitory effect of cystic fibrosis sputum on Adenovirus Mediated gene transfere in cultured epithelial cells. Hum Gene Ther 11, 1997 (2000)
70. Marchand-Pinatel, S., Planells, R., Merten, M.D., Kammouni, W., Figarella, C.: A quantitative multistandard reverse transcriptase-polymerase chain reaction assay of the cystic fibrosis transmembrane conductance regulate: its usefulness in studying efficiency of gene transfere. Anal Biochem 283, 200 (2000)
71. Harvey, B.G., Leopold, P.L., Hackett, N.R., Grasso, T.M., Williams, P.M., Tucker, A.L., Kaner, R.J., Ferris, B., Gonda, I., Sweeney, T.D., Ramalingam, R., Kovesdi, I., Shak, S., Crystal, R.G.: Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 10, 1245 (1999)
72. Chrimule, N., Propert, K., Magosin, S., Qian, Y., Qian, R., Wilson, J.: Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6, 1574 (1999)
73. Rochat, T.: Somatic gene therapy of mucoviscidosis using recombinant adenovirus: the start of a long course. Schweiz Med Wochenschr 127, 148 (1997)
74. Marchisone, C., Pfeffer, U., Del Grosso, F., Noonan, D.M., Santi, L., Albini, A.: Progress towards gene therapy for cancer. J Exp Clin Cancer Res 19, 261 (2000)
75. Dachs, G.U., Dougherty, G.J., Stratford, I.J., Chaplin, D.J.: Targeting gene therapy to cancer: a review. Oncol Res 9, 313 (1997)
76. Crystal, R.G.: In vivo and ex vivo gene therapy strategies to treat tumors using adnovirus gene transfere vectors. Cancer Chemother 43 Suppl, S90 (1999)
77. Alemany, R., Gomez-Manzano, C., Balague, C., Yung, W.K., Curiel, D.T., Kyritsis, A.P., Fueyo, J.: Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252, 1 (1999)
78. Clayman, G.L., Dreiling, L.: Local delivery for gene therapy. Curr Oncol Rep 1, 138 (1999)
79. O'Malley, B.W.Jr., Couch, M.E.: Gene therapy and strategies for head and neck cancer. Adv Otorhinolaryngol 56, 279 (2000)
80. Clayman, G.L., Frank, D.K., Bruso, P.A., Gopfert, H.: Adenovirus-mediated wild-type p53 gene tranfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5, 1715 (1999)
81. Khuri, F.R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I.F., Romel, L., Gore, M., Ironside, J., MacDougall, R.H., Heise, C., Randlev, B., Gillenwater, A.M., Bruso, P., Kaye, S.B., Hong, W.K., Kirn, D.H.: A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6, 879 (2000)
82. Morris, J.C., Ramsey, W.J., Wildner, O., Muslow, H.A., Aguilar-Cordova, E., Blease, R.M.: A phase I study of intralesional administration of an adenovirus vector expressing the HS-1 thymidine kinase gene (AdV.RSV.TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther 11, 487 (2000)
83. Swisher, S.G., Roth, J.A., Nemunaitis, J., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Connors, D.G., El-Naggar, A.K., Fossella, F., Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, J.S., Mack, M., Merritt, J.A., Nguyen, D.M., Nesbitt, J.C., Perez-Soler, R., Pisters, K.M., Putnam, J.B., Richli, W.R., Savin, M., Waugh, M.K.: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91, 763 (1999)
84. Schuler, M., Rochlitz, C., Horowitz, J.A., Schlegel, J., Perruchoud, A.P., Kommoss, F., Bollinger, C.T., Kauczor, H.U., Dalquen, P., Fritz, M.A., Swanson, S., Herrmann, R., Huber, C.: A phase I study of adenovirus-mediated wild-type p53 gene transfere in patients with advanced non-small-cell lung cancer. Hum Gene Ther 9, 2075 (1998)
85. Boulay, J.L., Perruchoud, A.P., Reuter, J., Bollinger, C., Herrmann, R., Rochlitz, C.: P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients. Cancer Gene Ther 7, 1215 (2000)
86. Roth, J.A., Swisher, S.G., Merrit, J.A., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., El-Naggar, A.K., Fossela, F.V., Glisson, B.S., Hong, W.K., Khurl, F.R., Kurie, J.M., Nesbitt, J.C., Pisters, K., Putman, J.B., Schrump, D.S., Shin, D.M., Walsh, G.L.: Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 replacement. Semin Oncol 25, 33 (1998)
87. Molinier-Frenkel, V., Boulaire, C.L., Gal, F.A., Gahery-Segard, H., Tursz, T., Guillett, J.G., Farace, F.: Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Hum Gene Ther 11, 1911 (2000)
88. Yen, N., Ioannides, C.G., Xu, K., Swisher, S.G., Lawrence, D.D., Kemp, B.L., El-Naggar, A.K., Cristiano, R.J., Fang, B., Glisson, B.S., Hong, W.K., Khuri, J.M., Lee, J.J., Lee, J.S., Merritt, J.A., Mukhopadhyay, T., Nesbitt, J.C., Nguyen, D., Perez-Soler, R., Pisters, M., Putnam, B.Jr., Schrump, D.S., Shin, D.M., Walsh, G.L., Roth, J.A.: Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. Cancer Gene Ther 7, 530 (2000)
89. Sterman, D.H., Treat, J., Litzky, L.A., Amin, K.M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J.M., Albelda, S.M., Kaiser, L.R.: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9, 1083 (1998)
90. Molnar-Kimber, K.L., Sterman, D.H., Chang, M., Kang, E.H., ElBash, M., Lanuti, M., Elshami, A., Gelfand, K., Wilson, J.M., Kaiser, L.R., Albelda, S.M.: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma Hum Gene Ther 9, 2121 (1998)
91. Wierda, W.G., Cantwell, M.J., Woods, S.J., Rassenti, L.Z., Prussak, C.E., Kipps, T.J.: CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia Blood 96, 2917 (2000)
92. Habib, N.A., Sarraf, C.E., Mitry, R.R., Havlik, R., Nicholls, J., Kelly, M., Vernin, C.C., Gueret-Wardle, D., El-Masry, R., Salama, H., Ahmed, R., Michail, N., Edward, E., Jensen, S.L.: ElB-deleted adenovirus (d11520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 12, 219 (2001)
93. Barnes, M.N., Pustilnik, T.B.: Current strategies in gene therapy for ovarian cancer. Curr Opin Obstet Gynecol 13, 47 (2001)
94. Hasenburg, A., Tong, X.W., Rojas-Martinez, A., Nyberg-Hoffman, C., Kievack, C.C., Kaplan, A.L., Kaufman, R.H., Ramzy, I., Aguilar-Cordova, E., Kieback, D.G.: Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilities outpatient treatment Anticancer Res 19, 2163 (1999)
95. Alvarez, R.D., Barnes, M.N., Gomez-Navarro, J., Wang, M., String, T.V., Arafat, R.B., Johnson, M.R., Roberts, B.L., Siegal, G.P., Curiel, D.T.: A cancer gene therapy approach utilizing an anti-erb-2 single chain antibody-encoding adenovirus (Ad21): a phase I trial. Clin Cancer Res 6, 3081 (2000)
96. Pagliaro, L.C.: Gene therapy for bladder cancer. World J Urol 18, 148 (2000)
97. Sweeney, P., Pisters, L.L.: Ad5CMVp53 gene therapy for locally advanced prostate cancer - where do we stand? World J Urol 18, 121 (2000)
98. Allay, J.A., Steiner, M.S., Zhang, Y., Reed, C.P., Cockroft, J., Lu, Y.: Adenovirus p16 gene therapy for prostate cancer. World J Urol 18, 111 (2000)
99. Herman, J.R., Adler, H.L., Aguilar-Cardova, E., Rojas-Martinez, A., Woo, S., Timme, T.L., Wheeler, T.M., Thompson, T.C., Scardino, P.T.: In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 10, 1239 (1999)
100. Shalev, M., Kadmon, D., Teh, B.S., Butler, E.B., Aguiler-Cordova, E., Thompson, T.C., Herman, J.R., Adler, H.L., Scardino, P.T., Miles, B.J.: Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 163, 1747 (2000)
101. O'Brien, T., Simari, R.D.: Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution. Mayo Clin Pro 75, 831 (2000)
102. Rosengart, T.K., Lee, L.Y., Patel, S.R., Kligfield, P.D., Okin, P.M., Hackett, N.R., Isom, O.W., Crystal, R.G.: Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 230, 466 (1999)
103. Lahti, K.G., Vale, P.R., Losordo, D.W., Cespedes, R.M., Symes, J.F., Esakof, D.D., Maysky, M., Isner, J.M.: Gene therapy with vascular endothelial growth factor for inoperable coronary disease: anesthetic management and results. Anesth Analg 92, 19 (2001)
104. Crombleholme, T.M.: Adenoviral-mediated gene transfer in wound healing. Wound Repair Regen 8, 460 (2000)
105. Margolis, D.J., Crombleholme, T., Herlyn, M.: Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 8, 480 (2000)
106. Chandler, L.A., Ma, C., Gonzalez, M.A., Doukas, J., Nguyen, T., Pierce, G.F., Phillips, M.L.: Matrix-enabled gene transfer for cutaneous wound repair. Wound Repair Regen 8, 473 (2000)
107. Hollon, T.: Researchers and regulators reflect on first gene therapy death. Nature Medicine 6, 6 (2000)
108. Marshal, E.: Gene therapy death prompts review of adenovirus vector. Science 286, 2244 (1999)